Eli Lilly And Co vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Eli Lilly And Co trades at $1,220.99 (market cap $1.08T), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.33. The key difference: Eli Lilly And Co pays a 0.57% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none. Which is the better fit depends on your goals.
| LLY | YMAG | |
|---|---|---|
Market Cap | $1.08T | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.24K | $15.98 |
52-Week Low | $639.43 | $10.76 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
YMAG trades at $11.29, down 2.59% today, with technical indicators showing a bullish overall signal despite mixed oscillators. The ETF maintains consistent weekly dividend distributions, with recent payouts ranging from $0.07 to $0.40 per share. Recent news highlights YieldMax's distribution announcements and analysis of the fund's option income strategy performance.
The fund's structured option strategy provides high income potential but faces NAV stability challenges during earnings volatility. Key risks include concentrated exposure to Magnificent Seven stocks and option strategy complexity. Technical support sits at $11-12 levels while the bullish moving average trend suggests potential upside momentum.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →